Skip to main navigation Skip to search Skip to main content

Precision Oncology: A Global Perspective on Implementation and Policy Development

  • Denis Horgan
  • , Marcel Tanner
  • , Charu Aggarwal
  • , David Thomas
  • , Surbhi Grover
  • , Lina Basel-Salmon
  • , Rodrigo Dienstmann
  • , Tira Jing Ying Tan
  • , Woong Yang Park
  • , Hadi Mohamad Abu Rasheed
  • , Lillian L. Siu
  • , Brigette Ma
  • , Rocío Ortiz-López
  • , Marc Van Den Bulcke
  • , Silvia Castillo Taucher
  • , Andrea Ferris
  • , Naureen Starling
  • , Umberto Malapelle
  • , John Longshore
  • , Hugo Alberto Barrera Saldaña
  • Vivek Subbiah
  • European Alliance for Personalised Medicine
  • International Cancer Patient Coalition
  • Swiss Tropical and Public Health Institute
  • University of Basel
  • University of Pennsylvania
  • University of New South Wales
  • Rabin Medical Center Israel
  • Tel Aviv University
  • Schneider Childrens Medical Center Israel
  • Vall d'Hebron Institute of Oncology
  • Oncoclínicas Precision Medicine
  • The University of Vic - Central University of Catalonia
  • National Cancer Centre
  • Qatar Cancer Society
  • Princess Margaret Cancer Centre
  • Chinese University of Hong Kong
  • Sciensano
  • Instituto Tecnologico de Estudios Superiores de Monterrey
  • Clínica Alemana de Santiago
  • National Institutes of Health
  • Royal Marsden NHS Foundation Trust
  • University of Naples Federico II
  • AstraZeneca
  • Universidad Autonoma de Nuevo Leon
  • Innbiogem SC-Vitagénesis SA at LANSEIDI-FarBiotec
  • Sarah Cannon Research Institute

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors - scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.

Original languageEnglish
Article numbere2400416
JournalJCO Global Oncology
Volume11
DOIs
StatePublished - 1 Jan 2025

Fingerprint

Dive into the research topics of 'Precision Oncology: A Global Perspective on Implementation and Policy Development'. Together they form a unique fingerprint.

Cite this